Additive anti-atherogenic effect of thromboxane receptor antagonism with 12/15lipoxygenase gene disruption in apolipoprotein E-deficient mice

Atherosclerosis

Volumn 199, Issue 2, 2008, Pages 265-270

  Tang, Liung ^a   Ding, Tao ^a   Praticò, Domenico ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

12 15Lipoxygenase; Atherosclerosis; Thromboxane

Indexed keywords

APOLIPOPROTEIN E; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ISOPROSTANE; PROSTACYCLIN; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AORTA DISEASE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; GENE DISRUPTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; URINALYSIS;

ANIMALS; ANTIOXIDANTS; APOLIPOPROTEINS E; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; ATHEROSCLEROSIS; GENE EXPRESSION REGULATION; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, THROMBOXANE; THROMBOSIS; THROMBOXANE A2; VITAMIN E;

EID: 47649125658     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.11.038     Document Type: Article

References (22)

1. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-872
2. Dogne J.M., Hanson J., and Praticò D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci 26 (2005) 639-644
3. Belton O., Byrne D., Kearny D., Leahy A., and Fitzgerald D.J. Cyxlooxygenase-1 and 2-depepndent prostacyclin formation in patients with atherosclerosis. Circulation 102 (2000) 840-845
4. Praticò D., Cyrus T., Li H., and Fitzgerald G. Endogenous biosynthesis of thromboxane and prostacyclin in two distinct murine models of atherosclerosis. Blood 96 (2000) 3823-3826
5. Praticò D., Cyrus T., Zhang Z., Li H., and Fitzgerald G. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor-deficient mice. Proc Natl Acad Sci USA 98 (2001) 3358-3363
6. Belton O., Duffy A., Toomey S., and Fitzgerald D.J. Cyxlooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108 (2003) 3017-3023
7. Cyrus T., Sung S., Zhao L., et al. Effect of low dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low density lipoprotein receptor deficient mice. Circulation 106 (2002) 1282-1287
8. Kobayashi T., Tahara Y., Matsumoto M., et al. Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114 (2004) 784-794
9. Cayatte A.J., Du Y., Oliver-Kraninski J., et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apoE-deficient mice. Arterioscler Thromb Vasc Biol 20 (2000) 1724-1728
10. Cyrus T., Yao Y., Ding T., Dogne J.M., and Praticò D. A novel thromboxane receptor antagonist and synthase inhibitor, BM573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. Eur J Pharmacol 561 (2007) 105-111
11. Kuhn H., and Thiele B. The diversity of the lipoxygenase family. Many sequences data but little information on biological significance. FEBS Lett 449 (1999) 7-11
12. Cyrus T., Praticò D., Zhao L., et al. Absence of 12/15lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice. Circulation 103 (2001) 2277-2282
13. Cyrus T., Witztum J.L., Rader D.J., et al. Disruption of 12/15LO-lipoxygenase gene diminishes atherosclerosis in apoE-deficient mice. J Clin Invest 103 (1999) 1597-1604
14. George J., Afek A., Shaish A., et al. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 104 (2001) 1646-1650
15. Zhao L., Cuff C.A., Moss E., et al. Selective interleukin 12 synthesis defect in 12/15-lipoxygenase deficient macrophages is associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem 277 (2001) 35350-35356
16. Harats D., Shaish A., George J., et al. Over-expression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 20 (2000) 2100-2105
17. Reilly K.B., Srinivasan S., Hatley M.E., et al. 12/15Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J Biol Chem 279 (2004) 9440-9450
18. Huo Y., Zhao L., Hyman M.C., et al. Critical role of macrophage 12/15lipoxygenase for atherosclerosis in apolipoprotein E deficient mice. Circulation 110 (2004) 2024-2031
19. Zhao L., Praticò D., Rader D.J., and Funk C.D. 12/15Lipoxygenase gene disruption and vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway. Prostaglandins Lipid Mediat 78 (2005) 185-193
20. Reiss A.B., and Glass A.D. Atherosclerosis: immune and inflammatory aspects. J Invest Med 54 (2006) 123-131
21. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 8 (2002) 1211-1217
22. Kinlay S., and Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol 98 (2006) 2P-8P